Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

TG4050 is becoming evaluated in two Section one medical trials. It combines Transgene’s proprietary myvac system with NEC’s reducing-edge Synthetic Intelligence (AI) abilities to decide on affected person-particular neoantigens

– Information confirm that the prediction algorithm efficiently identifies immunogenic cancer mutations, even amongst a massive set of prospect mutations

– Information will be offered at impending Digital AACR 2020 Session II

Image credit: Pixabay (Free of charge Pixabay license)

Transgene (Euronext Paris: TNG), a biotech business that designs and develops virus-centered immunotherapies for the remedy of cancer, and NEC Corporation (TSE: 6701), a chief in IT and community systems, today

Read More Read More

AI Finds Genes Related to the Sense of Smell Play a Role in Development of Cancer

A selection of former scientific tests have found that the roughly 400 olfactory genes existing in the human body are occasionally expressed over and above the nose, posing an intriguing issue for researchers associated in the area of genetics.

Now, a study posted in Molecular Methods Biology has proven that sufferers with colon cancer whose cells show the expression of certain odor-sensing genes are much more possible to experience much more significant sickness and have worse outcomes.

The expression of a gene only suggests the deployment of the info contained therein for making proteins or other molecules with unique effects

Read More Read More